Stocks · News reference

Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's Disease

Jul 9, 2026, 3:44 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 26, 2026, 10:24 PMSEC EDGAR
8-K filing — Serina Therapeutics, Inc. (SER)
Filed: 2026-08-27 AccNo: 0001708599-26-000051 Size: 254 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
SER
BenzingaAug 24, 2026, 9:32 PMBenzinga Newsdesk
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
-SEC Filing
SER
BenzingaAug 13, 2026, 8:47 PMBenzinga Newsdesk
Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.47) by 19.57 percent. This is a 16.67 percent increase over losses of $(0.66) per share
SER
BenzingaJul 23, 2026, 10:10 AMBenzinga Newsdesk
Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease
- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in
SER